Table 1.

[¹¹C]-Erlotinib Tumor Imaging and Data Acquisition Parameters for Both High and Low SA Conditions.

Xenograft	EGFR Properties	SA	n	Voxels		R1		BP		SUV
SW620	WT*	High	1	100	n/a	1	n/a	-1	n/a	0.28	n/a
HCC827	Exon 19 del (E746-A750)		3	168	(13)	1.12	(0.22)	6.38	(1.90)	0.91	(0.60)
PC9	Exon 19 del (E746-A750)		3	82	(50)	0.787	(0.27)	2.45	(1.72)	0.45	(0.31)
U87	WT		3	102	(16)	1.3	(0.07)	-0.69	(0.53)	0.51	(0.56)
U87Δ	ΔEGFR		3	124	(23)	0.23	(0.08)	-0.13	(0.20)	0.46	(0.29)
SW620	WT*	Low	1	42	n/a	1.24	n/a	-1	n/a	0.08	n/a
HCC827	Exon 19 del (E746-A750)		3	153	(57)	0.49	(0.35)	0.38	(0.27)	0.93	(1.33)
PC9	Exon 19 del (E746-A750)		3	72	(49)	0.53	(0.53)	0.12	(0.40)	0.48	(0.67)
U87	WT		2	100	(25)	1.75	(0.58)	-0.43	(0.81)	0.33	(0.30)
U87Δ	ΔEGFR		2	106	(62)	0.57	(0.27)	0.16	(0.79)	0.24	(0.16)

The mean number of voxels per ROI is reported along with SRTM calculated parameters and SUVs calculated at 90 minutes. Average R₁ and BP values are used to quantify delivery of [¹¹C]-erlotinib and receptor density, respectively. All values are shown as an average across sample size n with the SD in parentheses.

^*The WT EGFR of SW620 is not expressed at detectable levels.